[Experience in complex therapy ribavine chronic viral hepatitis C].
In 72 patients with chronic hepatitis C aged 18 to 62 years evaluated the clinical efficacy Ribavine in combination therapy with interferon-alpha. The safety, good tolerability and efficacy Ribavine. Persistent virological and biochemical response in the application of interferon-alpha and Ribavine obtained from 47,5 to 53,1%. Recurrence rate was 32,5% in patients with genotype 1 and 21,9% with genotype 2 and 3. Side effects of Ribavine are reversible and leveled after the completion of therapy.